the o2h S/EIS fund - o2h Ventures

The o2h human health S/EIS fund is a hybrid fund that is investing in EIS and SEIS qualifying seed stage companies covering novel drug discovery along with enabling services, tools and AI technologies.

featured in

highlights

                                    Fund is now closed and cannot accept any further subscriptions .                                        
Full deployment planned by end of tax year 2020/21.                                        
Deployed more than 65% of the funds in a diversed portfolio of 16 companies.                                        
More than 50% of investors' subscription has been fully deployed within 12-18 months.

fund overview

AUM	£ 3.12m
Minimum Subs.	£ 25k
Maximum Subs	-

EIS tax relief is very attractive for UK tax payers

You invest £50k

EIS gives you £15k tax relief from HMRC

EIS gives you £25k tax relief from HMRC

IF COMPANY VALUE DOUBLES

Investment now worth £100k

£50k profit

+ £15k income tax relief

- £10k performance incentive

= £55k net profit

IF VALUE STAYS THE SAME

Investment still worth £50k

£0 profit

+ £15k income tax relief

- £0 performance incentive

= £15k net profit

IF COMPANY FAILS

Investment now worth £0

£50k loss

+ £15k income tax relief

+ £15,750 loss relief *

- £0 performance incentive

= £19,250 capital loss

* Loss relief calculated on higher rate tax bracket Worked example is net of any fund fees

*Tax relief depends on an individual’s circumstances and may change in the future.

why o2h ventures?

+History in grassroots science: We have a track record of nurturing and investing in emerging life science and tech companies – the o2h ventures team are leaders in the biotech community and have been involved as investors, holding various board/industry positions awe well as being engaged in grassroot scientific activity for over 20 years.

+Evaluation: Since its inception, the o2h group has developed a rigorous process to evaluate its deal flow, particularly regards seed investments. Opportunities come from a wide range of sources, as a result of the o2h group’s extensive network of contacts.

+Access to scientific talents: The team have developed access to some of the most interesting scientific ideas and talent in the UK, achieving a clearly differentiated position through its live working relationships, fostered over many years, working as a discovery services company. This potentially fives o2h ventures earlier access than competitor to some of the most promising companies.

+Business model: The business model identified by o2h ventures gives it an edge both in terms of access to opportunities as well as an understanding of the support they require post investment in terms of incubation. By combining access and incubation we are providing a unique opportunity, reducing investment risk by being deeply involved and the team believe that this will increase Fund’s prospects of making successful exits.

fund registered with